Menu

Rothwell Figg BiosimilarIP Blog

Skip navigation Menu
  • Regulatory
  • Legal
  • News
  • About RFEM
  • Search

You are here:

  1. Home
  2. PTAB Denies Inter Partes Review of Rituxan® Patents
  3. IPR2017-02127
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

ShareEmail, Linked In, Twitter, Facebook, Google Plus

Print

IPR2017-02127

By: Caroline Britt May 10, 2018, 3:37 pm Comments are off

IPR2017-02127

ShareFacebook, Twitter, Google Plus, Pinterest, Email

See more

  • Previous entry PTAB Denies Inter Partes Review of Rituxan® Patents
  • Back All Entries

Sign Up for Updates

Don’t worry. We don’t spam.

Practice Contacts

  • E. Anthony Figg

  • Joseph A. Hynds

  • Seth Cockrum

Featured Posts

  • U.S. – E.U. Mutual Recognition Agreement Will Reduce Costs

    August 1, 2019

  • House Democrats Seek to Remove Biologics Exclusivity Period From USMCA

    July 25, 2019

  • What Pharma Companies Must Do Globally to Benefit From Canada’s Patent Term Extension Framework

    July 22, 2019

Popular Tags

AbbVie adalimumab Amgen Avastin® bevacizumab Biocon Biogen Boehringer Ingelheim BPCIA Celltrion District Court EMA FDA Featured Federal Circuit Genentech Herceptin® Hospira Humira® Infliximab IPR Janssen Legal Litigation Mylan Neulasta® News Notice Requirement Patent Dance pegfilgrastim Pfizer PTAB Regeneron Regulatory Remicade® Rituxan® Rituximab Roche Samsung Bioepsis Sandoz Sanofi Supreme Court Teva trastuzumab USPTO
Opinions expressed in articles on www.BiosimilarsIP.com are solely those of the author only and do not necessarily reflect the views of Rothwell Figg Ernst & Manbeck, P.C., its clients, or any of its respective affiliates. These materials are for general information purposes only and should not be taken as legal advice per the full disclaimer below.

Contact Us

Email Us
202.783.6040
Our Location

Find Out More

  • About Us
  • Results
  • Careers
  • Practices
  • Publications
  • News & Events
  • Professionals

© 2019 Rothwell, Figg, Ernst & Manbeck, P.C. All Rights Reserved

  • Disclaimer
  • Privacy Policy
Back to Top